Company news

Ocugen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocugen Provides Business Update with First Quarter 2023 Financial Results

May 4, 2023

Ocugen to Host Conference Call on Friday, May 5 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

April 27, 2023

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

April 26, 2023

Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

April 25, 2023

Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting

April 19, 2023

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

April 13, 2023

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

April 10, 2023

Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress

March 30, 2023

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

March 26, 2023

Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

March 6, 2023

Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

March 5, 2023

Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

February 26, 2023

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

February 16, 2023

Ocugen to Host Conference Call on Tuesday, February 28 at 8: 30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

February 14, 2023

Ocugen Appoints Quan A. Vu as Chief Business Officer

January 31, 2023

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

January 30, 2023

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

January 8, 2023

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

December 15, 2022

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

December 14, 2022

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

December 12, 2022

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

December 6, 2022

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

November 27, 2022

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

November 7, 2022

Ocugen to Host Conference Call on Tuesday, November 8 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

October 26, 2022

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

October 18, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

October 11, 2022

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

October 5, 2022

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 28, 2022

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

September 27, 2022

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 15, 2022

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

September 13, 2022

Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

September 7, 2022

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

August 31, 2022

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 11, 2022

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

August 4, 2022

Ocugen To Host Conference Call on Friday, August 5 at 8: 30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

July 28, 2022

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

June 20, 2022

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

June 13, 2022

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

June 12, 2022

Ocugen, Inc. to Present at BIO International Convention 2022

June 8, 2022

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

May 23, 2022

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

May 22, 2022

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

May 22, 2022

Ocugen Provides Business Update and First Quarter 2022 Financial Results

May 5, 2022

Ocugen to Host Conference Call on Friday, May 6 at 8: 30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

May 1, 2022

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 28, 2022

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

April 24, 2022

Ocugen, Inc. to Present at NobleCon18

April 18, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.